Ondansetron Accord

Ondansetron, the active ingredient in Ondansetron Accord, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Ondansetron Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron Accord is a selective 5‑HT3 receptor antagonist used to prevent and treat nausea and vomiting in several clinical settings.

- Chemotherapy‑induced nausea and vomiting: Reduces the frequency and severity of acute and delayed episodes. - Radiation‑induced nausea and vomiting: Helps control nausea during and after radiotherapy. - Post‑operative nausea and vomiting: Decreases the incidence of nausea and vomiting after surgery. - Pregnancy‑related hyperemesis gravidarum (off‑label): May be used when conventional therapy fails, under specialist supervision.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement difficulty. - Diarrhoea: loose stools, usually transient. - Fatigue: feeling of tiredness or reduced energy. - Dizziness: light‑headed sensation. - Injection site reactions (if applicable): mild erythema or discomfort.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high doses. - Severe hypersensitivity: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, fever when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Neuroleptic malignant‑like syndrome: rare extrapyramidal signs. - Persistent visual disturbances: blurred vision or photophobia.

Before prescribing Ondansetron Accord, consider the following precautions:

- Cardiac risk assessment: evaluate baseline ECG in patients with known cardiac disease. - Electrolyte monitoring: correct hypokalaemia, hypomagnesemia, or hypocalcaemia before use. - Drug‑interaction review: avoid concurrent use with other QT‑prolonging agents. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Renal or hepatic impairment: dose adjustment may be required based on clinical judgement. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines that affect cardiac rhythm or serotonin pathways.

Major Interactions (Avoid): - Other QT‑prolonging drugs (e.g., quinidine, haloperidol): increase risk of arrhythmia. - Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): raise ondansetron plasma levels. - CYP2D6 substrates (e.g., metoprolol, codeine): may have altered metabolism. - Antacids containing aluminium or magnesium: can reduce oral absorption. - Digoxin: modest increase in serum concentrations. - Alcohol: may enhance central nervous system depression.